$96.32−2.92 (−2.94%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Oruka Therapeutics (ORKA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
10 figures withheld by our checks. Each blank figure names its reason.
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Capex step-up ($209.0K). Visible in the receipts below.
The lines that matter · FY19–FY25
Revenue ($M)—
0.0
FY19→FY25CAGR —
Net income ($M)▼962.2%
−105.4
FY19→FY25CAGR —
Free cash flow ($M)▼710.1%
−88.4
capex stepped upCAGR —
What the receipts whisper · what a headline number hides
Share count
+0.0%
45.8mn → 45.8mn diluted shares since FY25. Broadly flat, so EPS moves with net income rather than with the share count.
Capex step-up
$209.0K
▲10350% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY19–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY19–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.3191, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY22 | FY21 | FY20 | FY19 | YoY | CAGR 19→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 153,738.0 | 100,640.0 | 4,749.0 | 13,832.0 | 4,992.0 | 1,833.0 | ▲2019.2% | +172.2% |
Selling, general & admin | 29,370.0 | 21,411.0 | 5,847.0 | 5,503.0 | 4,774.0 | 3,981.0 | ▲266.2% | +52.3% |
Total operating expenses | 183,108.0 | 122,051.0 | 10,596.0 | 19,335.0 | 9,766.0 | 5,814.0 | ▲1051.9% | +114.1% |
Operating incomefeeds ROC rank | −183,108.0 | −122,051.0 | −10,596.0 | −19,335.0 | −9,766.0 | −5,814.0 | ▼1051.9% | — |
Other income, net | 30,534.0 | 16,618.0 | 670.0 | 13.0 | 19.0 | 165.0 | — | — |
Pretax income | −152,574.0 | −105,433.0 | −9,926.0 | −19,322.0 | −9,747.0 | −5,649.0 | ▼962.2% | — |
Income tax | — | — | — | — | −9.0 | −167.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −152,574.0 | −105,433.0 | −9,926.0 | −19,322.0 | −9,738.0 | −5,482.0 | ▼962.2% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | —A | —A | —A | —A | —A | —A | — | — |
Diluted shares (mn) | 143.37 | 45.75 | 1.20 | 1.16 | 0.39 | 0.11 | ▲3709.9% | +351.5% |
| Margins | ||||||||
† TTM = trailing four quarters through 2026-09-30.A Withheld by our checks.
5 more years of statements and CSV export are on Premium, and 9 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

